xazal 0,5 mg/ml solucion oral
ucb pharma s.a. - levocetirizina dihidrocloruro - soluciÓn oral - 0,5 mg/ml - levocetirizina dihidrocloruro 0,5 mg - levocetirizina
xazal 5 mg comprimidos recubiertos con pelicula
ucb pharma s.a. - levocetirizina dihidrocloruro - comprimido recubierto con pelÍcula - 5 mg - levocetirizina dihidrocloruro 5 mg - levocetirizina
xazal 5 mg/ml gotas orales en solucion
ucb pharma s.a. - levocetirizina dihidrocloruro - gotas orales en soluciÓn - 5 mg/ml - levocetirizina dihidrocloruro 5 mg - levocetirizina
briviact (in italy: nubriveo)
ucb pharma sa - brivaracetam - epilepsia - los antiepilépticos, - briviact está indicado como terapia adyuvante en el tratamiento de las crisis de inicio parcial con o sin generalización secundaria en adultos y adolescentes a partir de 16 años de edad con epilepsia.
vimpat
ucb pharma sa - lacosamida - epilepsia - los antiepilépticos, - vimpat está indicado como monoterapia y terapia adyuvante en el tratamiento de las crisis de inicio parcial con o sin generalización secundaria en adultos, adolescentes y niños a partir de los 4 años con epilepsia.
xyrem
ucb pharma ltd - oxibato de sodio - cataplexy; narcolepsy - otras drogas del sistema nervioso - tratamiento de la narcolepsia con cataplejía en pacientes adultos.
evenity
ucb pharma s.a. - romosozumab - osteoporosis - medicamentos para el tratamiento de enfermedades óseas - evenity está indicado en el tratamiento de la osteoporosis severa en mujeres posmenopáusicas con alto riesgo de fractura.
fintepla
ucb pharma s.a. - fenfluramine hydrochloride - epilepsies, myoclonic - los antiepilépticos, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.
bimzelx
ucb pharma s.a. - bimekizumab - psoriasis - inmunosupresores - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
cimzia
ucb pharma [be] belgium - certolizumab pegol 200,00 mg/ml - soluciÓn inyectable - cada 1 ml contiene: certolizumab pegol 200,00 mg